CD163 and cancer: The phenotype of CD163+ cells is known to resemble alternatively activated, anti-inflammatory M2 macrophages, and several clinicopathologic studies of cancer have demonstrated that CD163+ macrophages are associated with tumor growth/progression and a worse prognosis18–20.